Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Accumulated Depreciation & Amortization (2016 - 2025)

Ligand Pharmaceuticals' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $33.8 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 4.15% year-over-year to $33.8 million; the TTM value through Dec 2025 reached $33.8 million, down 4.15%, while the annual FY2025 figure was $33.8 million, 4.15% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $33.8 million at Ligand Pharmaceuticals, down from $35.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $51.5 million in Q4 2022 and bottomed at $33.8 million in Q4 2025.
  • The 5-year median for Accumulated Depreciation & Amortization is $36.5 million (2023), against an average of $41.6 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 98.79% in 2021 before it dropped 29.13% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $51.1 million in 2021, then increased by 0.91% to $51.5 million in 2022, then dropped by 29.13% to $36.5 million in 2023, then fell by 3.51% to $35.2 million in 2024, then dropped by 4.15% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Accumulated Depreciation & Amortization are $33.8 million (Q4 2025), $35.2 million (Q4 2024), and $36.5 million (Q4 2023).